Brexit: the European Parliament’s role in prioritising patients, public health and health security across Europe

9-11 am 27 September 2018, ROOM 4Q2, European Parliament

With the Brexit clock ticking and with only six months left until the United Kingdom leaves the European Union, both sides are now preparing for a ‘no deal’ Brexit, which could have implications on patient and public health across the EU27.

The European health community will express their concern, that with time running out, no substantial progress has been made in the negotiations on those areas effecting patient and public health. They call on parliamentarians and negotiators to ensure that the health of EU citizens is kept at the top of the agenda and will also consider what can be done to ensure public health and health security are prioritised.

The event will be moderated by Professor Gerd R. Burmester.

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 – 9:25</td>
<td><strong>Registration and networking</strong></td>
</tr>
<tr>
<td>9:25 – 9:35</td>
<td><strong>Opening remarks:</strong> Professor Gerd R Burmester EULAR</td>
</tr>
<tr>
<td>9:35 – 9:45</td>
<td><strong>The patient organisation perspective</strong></td>
</tr>
<tr>
<td></td>
<td>- Derick Mitchell – Chief Executive of The Irish Platform for Patient Organisations, Science and Industry</td>
</tr>
<tr>
<td>9:45 – 9:55</td>
<td><strong>How a post-Brexit EU-UK trade/withdrawal agreement needs to take account of public health objectives</strong></td>
</tr>
<tr>
<td></td>
<td>- Dr Gabriel Siles-Brügge - Associate Professor, Department of Politics and International Studies, University of Warwick: EPHA Scientific Advisor on Trade Policy</td>
</tr>
<tr>
<td>9:55 – 10:15</td>
<td><strong>Critical value of collaboration in research</strong></td>
</tr>
<tr>
<td></td>
<td>- Professor Stafford Lightman MBChir, Ph.D.(Cantab.), FMedSci, FRCP, Professor of Medicine at the University of Bristol</td>
</tr>
<tr>
<td></td>
<td>- Professor Wilfried Ellmeier, PhD, Professor of Immunobiology, Medical University of Vienna, President Elect of the BioMed Alliance</td>
</tr>
<tr>
<td>10:15 – 10:25</td>
<td><strong>Access to and safety of medicines and medical technologies</strong></td>
</tr>
<tr>
<td></td>
<td>- Yvonne Stewart: Head of Brexit Implementation GSK</td>
</tr>
<tr>
<td>10:25 – 10:50</td>
<td><strong>Question and answer session</strong></td>
</tr>
<tr>
<td></td>
<td>- Moderated by Professor Gerd R. Burmester</td>
</tr>
<tr>
<td>10:50 – 11:00</td>
<td><strong>Concluding remarks</strong></td>
</tr>
<tr>
<td></td>
<td>- Adina-Ioana Vălean MEP – Chair of the Committee on the Environment, Public Health and Food Safety</td>
</tr>
</tbody>
</table>
Aim of the event

The aim of this event is to discuss the impact of Brexit on the EU 27. This event has been organised by 18 EU-level health organisations who have come together to ensure that the needs of patients are prioritised during the Brexit negotiations, and will discuss the following topics:

- The patient organisation perspective
- Importance of EU public health infrastructure
- The critical value of collaboration in research
- The value of collaboration across Europe in Horizon Europe
- Access to and safety of medicines and medical technologies

This event will explore what steps can be taken by EU decision-makers to ensure patients and public health are kept at the top of the agenda during the negotiations. It will also consider what can be done to ensure public health and health security are prioritised. The Group will warn that there remain many unanswered questions, which will ‘determine the risk of Brexit’s impact on patients and public health across Europe’. The questions to be explored include:

- In the event of ‘no deal’ and realising we are running out of time, how would EU27 national governments mitigate any negative effects of Brexit on healthcare?
- How will a future deal ensure sufficient and timely supply of drugs and medical devices for both EU and UK patients?
- What kind of agreement will the UK and EU need to ensure the future medicine and med tech licensing system does not exacerbate delays in access to the most innovative treatments for patients, both in the UK and across the EU?
- How can we ensure a common framework for collaboration in pan-European research, innovation networks and clinical trials, post Brexit?

In December 2017, the group of 18 issued a joint policy statement which outlined five priorities:

- Bring close cooperation between the EU and UK on the regulation of medicines and medical technologies, to ensure that UK and EU patients will continue to have access to life-saving medicines and medical technologies.
- Establish a common framework for collaboration in research and information sharing between the EU27 and the UK.
- Ensure that there are continued reciprocal healthcare arrangements between the EU and UK.
- Develop strong coordination between the EU and UK on public health, including in pandemic preparation and disease prevention programmes.
- Ensure EU and UK health professionals continue to benefit from mutually beneficial training and education opportunities, with automatic recognition of qualifications.

Speaker Biographies

**Professor Gerd R. Burmester**

[Image of Professor Gerd R. Burmester]

Prof. Gerd R. Burmester is member of the Steering Group and Past President of the European League Against Rheumatism (EULAR). Prior to this he was Chair of the EULAR Standing Committee of Investigative Rheumatology 2003-2006 and Chairman of the Scientific Programme Committee of the EULAR Congress in Berlin, Germany in 2004. Prof. Burmester was also President of the German Society of Rheumatology from 2001-2002.

He is currently Professor of Medicine in the Department of Rheumatology and Clinical Immunology at the Charité University Hospital, Free University and Humboldt University of Berlin, Germany.

**Dr Derick Mitchell**

[Image of Dr Derick Mitchell]

Dr Derick Mitchell is the Chief Executive of The Irish Platform for Patient Organisations, Science and Industry (IPPOSI). Derick has over ten years’ experience of working in patient involvement, multi-stakeholder management, scientific communications and advocacy at both the national and European level and has a strong interest in the area of patient and public involvement in research.

Derick leads IPPOSI's participation in the European Patients Academy (EUPATI), an initiative which is training patients to become involved in the medicines R&D process and has spread the IPPOSI public-private partnership model to over 20 countries.
Dr Gabriel Siles-Brügge

Dr Gabriel Siles-Brügge is an Associate Professor in Public Policy and the Programme Director for the MA in Public Policy.

Gabriel joined PAIS in September 2016 from the University of Manchester, where he was a Lecturer in Politics. Before that, Gabriel was a Lecturer in International Political Economy at Oxford Brookes University. He holds a PhD from the University of Sheffield.

He has been a visiting scholar in the Department of Political Science at the University of Copenhagen (February-July 2015) and the Centre for EU Studies at Ghent University (November-December 2014).

Professor Stafford Lightman MBBChir.

Stafford Lightman is Professor of Medicine at the University of Bristol in the United Kingdom and is Director of the Henry Wellcome Laboratories for Integrative Neuroscience and Endocrinology. He started his scientific career working on catecholamines and opioid peptides with Leslie Iversen at the University of Cambridge and provided some of the first data linking opioid peptides with the regulation of neurohypophysial function.

Stafford Lightman was the founder Editor-in-Chief of the Journal of Neuroendocrinology, a founder Fellow of the Faculty of Medical Sciences, the founder Chairman of the Pituitary Foundation and a Council Member of the Physiological Society. He sits on several Research Councils, Wellcome Trust and European Research Committees and has Chaired the European Union Committee Review of Tertiary Education in East Africa. Professor Lightman also has a major interest in inter-relationships between art and neuroscience and is a frequent speaker on both radio and television.
Professor Wilfried Ellmeier

Wilfried Ellmeier studied biochemistry, performed his PhD thesis at the Research Institute of Molecular Pathology in Vienna (IMP) and graduated from the University of Vienna (1994). He performed his postdoctoral studies in immunology at the Skirball Institute, NYU Medical Center, USA (1995-1999) and subsequently established his independent research group in Vienna at the Institute of Immunology (2000).

Wilfried Ellmeier was appointed in 2007 to a Full Professor of Immunobiology and since then he is heading the Division of Immunobiology at the Institute of Immunology, Medical University of Vienna. His research focuses on transcriptional and epigenetic mechanisms that regulate T cell-mediated immunity. Since 2016 he is a board member and treasurer of the Alliance of Biomedical Research in Europe.

Yvonne Stewart

Yvonne Stewart is the Head of Brexit Implementation at GSK. Yvonne is a pharmacist with a PhD in Pharmaceutical Sciences and she has more than 15 years of experience with GSK. Prior to her appointment as Head of Brexit Implementation, Yvonne has held a wide variety of roles in Quality and Regulatory across Research & Development, EU Commercial and Global Manufacturing & Supply. Yvonne is a member of the EFPIA Brexit Task Force, the EFPIA Supply Chain Working Group and is the current Chair of the EFPIA Drug Shortages team. In the UK, Yvonne is a member of both the ABPI-BIA Brexit Task force and ABPI Pharmaceutical Quality Expert Network.
Adina-Ioana Vălean MEP

Chair - Environment, Public Health and Food Safety

Adina Valean has a Master's Degree in European Integration and Security Studies, postgraduate studies in National Security and Defence Management and a degree in mathematics. She started her professional career as a maths teacher in Bucharest. Before becoming a politician, she was a social activist, member of several foundations and associations promoting tolerance, dialogue and a liberal economic market.

Adina Valean is a member of the Romanian National Liberal Party and was a Member of the Romanian Parliament from 2004 to 2006. Her activities focused on market and labour issues. She was also Secretary-General of the National Liberal Party’s youth wing and Secretary of the National Liberal Party Committee on business, privatisation and competition policy.

As an MEP, she was Rapporteur on the Connecting Europe Facility, a financing instrument which will fund €33.2 billion worth of investment to improve Europe's transport, energy and digital networks. Furthermore, as Rapporteur on the 2009 Roaming Regulation and Shadow on the subsequent dossiers, she kick-started the gradual plunge in roaming charges inside the EU, charges that were finally eliminated in 2015.